Symbols / TCRX
TCRX Chart
About
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 59.59M |
| Enterprise Value | -29.25M | Income | -142.60M | Sales | 8.42M |
| Book/sh | 2.54 | Cash/sh | 3.25 | Dividend Yield | — |
| Payout | 0.00% | Employees | 146 | IPO | — |
| P/E | — | Forward P/E | -1.05 | PEG | — |
| P/S | 7.07 | P/B | 0.41 | P/C | — |
| EV/EBITDA | 0.20 | EV/Sales | -3.47 | Quick Ratio | 6.32 |
| Current Ratio | 6.44 | Debt/Eq | 66.39 | LT Debt/Eq | — |
| EPS (ttm) | -1.18 | EPS next Y | -1.00 | EPS Growth | — |
| Revenue Growth | 139.40% | Earnings | 2025-11-12 08:00 | ROA | -30.45% |
| ROE | -76.44% | ROIC | — | Gross Margin | -148.85% |
| Oper. Margin | -14.76% | Profit Margin | 0.00% | Shs Outstand | 52.47M |
| Shs Float | 47.12M | Short Float | 5.50% | Short Ratio | 4.95 |
| Short Interest | — | 52W High | 2.57 | 52W Low | 0.88 |
| Beta | 1.04 | Avg Volume | 600.55K | Volume | 359.41K |
| Target Price | $6.00 | Recom | Buy | Prev Close | $1.01 |
| Price | $1.05 | Change | 3.96% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$1.05
Latest analyst target
3. DCF / Fair value
$-30.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.05
Low
$5.00
High
$7.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-13 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-11-04 | down | BTIG | Buy → Neutral | — |
| 2025-11-04 | main | Needham | Buy → Buy | $6 |
| 2025-05-07 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-04-08 | reit | Needham | Buy → Buy | $9 |
| 2025-03-07 | main | Barclays | Overweight → Overweight | $3 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-05 | main | Needham | Buy → Buy | $9 |
| 2024-12-11 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-12-11 | reit | Needham | Buy → Buy | $11 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-11-12 | reit | Needham | Buy → Buy | $11 |
| 2024-11-06 | reit | Needham | Buy → Buy | $11 |
| 2024-08-13 | reit | Wedbush | Outperform → Outperform | $10 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-12 | reit | Needham | Buy → Buy | $11 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-05-16 | init | BTIG | — → Buy | $12 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-05-13 | reit | Needham | Buy → Buy | $11 |
- TScan Therapeutics (TCRX) Price Target Increased by 10.53% to 7.14 - Nasdaq Sat, 06 Dec 2025 08
- Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment - Investing.com Mon, 03 Nov 2025 08
- TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- TScan Therapeutics (NASDAQ: TCRX) extends cash runway to H2 2027; cuts workforce about 30% - Stock Titan Mon, 03 Nov 2025 08
- New Analyst Forecast: $TCRX Given $6.0 Price Target | TCRX Stock News - Quiver Quantitative ue, 04 Nov 2025 08
- Great week for TScan Therapeutics, Inc. (NASDAQ:TCRX) institutional investors after losing 73% over the previous year - simplywall.st Fri, 11 Jul 2025 07
- 2 Overlooked Stocks to Snap Up in 2025 - Barchart.com hu, 16 Oct 2025 07
- TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire Wed, 12 Nov 2025 08
- TScan Therapeutics Shifts Focus to Hematologic Malignancies - TipRanks Mon, 03 Nov 2025 08
- TScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely - Yahoo Finance Fri, 15 Aug 2025 07
- HC Wainwright & Co. Maintains TScan Therapeutics (TCRX) Buy Recommendation - Nasdaq hu, 13 Nov 2025 08
- TCRX Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 02
- TScan Therapeutics Second Quarter 2025 Earnings: Beats Expectations - simplywall.st hu, 14 Aug 2025 07
- TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewswire Wed, 05 Nov 2025 08
- BTIG downgrades Tscan Therapeutics stock to Neutral on program delays - Investing.com ue, 04 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 161801 | 145526 | — | Purchase at price 0.90 per share. | LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-23 00:00:00 | I |
| 1 | 2588794 | 3106553 | — | Purchase at price 1.20 per share. | LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-20 00:00:00 | I |
| 2 | 131800 | 385769 | — | Purchase at price 2.90 - 3.01 per share. | LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-13 00:00:00 | I |
| 3 | 947 | 4114 | — | Purchase at price 4.34 per share. | LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-15 00:00:00 | I |
| 4 | 5000 | 26450 | — | Purchase at price 5.29 per share. | KLENCKE BARBARA M.D. | Director | — | 2024-09-23 00:00:00 | D |
| 5 | 10000 | 56100 | — | Purchase at price 5.53 - 5.69 per share. | KLENCKE BARBARA M.D. | Director | — | 2024-08-26 00:00:00 | D |
| 6 | 164686 | 952116 | — | Sale at price 5.78 per share. | ZDRAVESKI ZORAN | Officer | — | 2024-08-23 00:00:00 | D |
| 7 | 157186 | 531520 | — | Conversion of Exercise of derivative security at price 1.81 - 4.85 per share. | ZDRAVESKI ZORAN | Officer | — | 2024-08-23 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -118.65M | -80.10M | -59.91M | -45.30M |
| TotalUnusualItems | -1.09M | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | -1.09M | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -127.50M | -89.22M | -66.22M | -48.62M |
| ReconciledDepreciation | 4.11M | 5.36M | 5.14M | 3.33M |
| EBITDA | -119.74M | -80.10M | -59.91M | -45.30M |
| EBIT | -123.85M | -85.46M | -65.05M | -48.62M |
| NetInterestIncome | 8.41M | 4.24M | 415.00K | 16.00K |
| InterestExpense | 3.65M | 3.76M | 1.18M | 0.00 |
| InterestIncome | 12.06M | 8.00M | 1.59M | 16.00K |
| NormalizedIncome | -126.41M | -89.22M | -66.22M | -48.62M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -127.50M | -89.22M | -66.22M | -48.62M |
| TotalExpenses | 137.64M | 114.51M | 80.17M | 58.78M |
| TotalOperatingIncomeAsReported | -134.82M | -93.46M | -66.64M | -48.64M |
| DilutedAverageShares | 111.99M | 65.60M | 24.05M | 11.66M |
| BasicAverageShares | 111.99M | 65.60M | 24.05M | 11.66M |
| DilutedEPS | -1.14 | -1.36 | -2.75 | -4.17 |
| BasicEPS | -1.14 | -1.36 | -2.75 | -4.17 |
| DilutedNIAvailtoComStockholders | -127.50M | -89.22M | -66.22M | -48.62M |
| NetIncomeCommonStockholders | -127.50M | -89.22M | -66.22M | -48.62M |
| NetIncome | -127.50M | -89.22M | -66.22M | -48.62M |
| NetIncomeIncludingNoncontrollingInterests | -127.50M | -89.22M | -66.22M | -48.62M |
| NetIncomeContinuousOperations | -127.50M | -89.22M | -66.22M | -48.62M |
| PretaxIncome | -127.50M | -89.22M | -66.22M | -48.62M |
| OtherIncomeExpense | -1.09M | |||
| SpecialIncomeCharges | -1.09M | 0.00 | ||
| OtherSpecialCharges | 1.09M | |||
| NetNonOperatingInterestIncomeExpense | 8.41M | 4.24M | 415.00K | 16.00K |
| TotalOtherFinanceCost | -16.00K | |||
| InterestExpenseNonOperating | 3.65M | 3.76M | 1.18M | 0.00 |
| InterestIncomeNonOperating | 12.06M | 8.00M | 1.59M | 16.00K |
| OperatingIncome | -134.82M | -93.46M | -66.64M | -48.64M |
| OperatingExpense | 137.64M | 114.51M | 80.17M | 58.78M |
| DepreciationAmortizationDepletionIncomeStatement | 728.00K | 862.00K | ||
| DepreciationAndAmortizationInIncomeStatement | 728.00K | 862.00K | ||
| DepreciationIncomeStatement | 728.00K | 862.00K | ||
| ResearchAndDevelopment | 107.35M | 88.15M | 59.82M | 44.95M |
| SellingGeneralAndAdministration | 29.56M | 25.49M | 20.35M | 13.83M |
| GeneralAndAdministrativeExpense | 29.56M | 25.49M | 20.35M | 13.83M |
| OtherGandA | 13.96M | 14.10M | 8.70M | 7.15M |
| SalariesAndWages | 15.60M | 11.40M | 11.65M | 6.68M |
| TotalRevenue | 2.82M | 21.05M | 13.54M | 10.14M |
| OperatingRevenue | 2.82M | 21.05M | 13.54M | 10.14M |
| Line Item | 2023-12-31 | 2021-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 116.87K | ||
| OrdinarySharesNumber | 56.59M | 47.83M | 24.23M | 23.91M |
| ShareIssued | 56.59M | 47.83M | 24.23M | 24.02M |
| TotalDebt | 97.38M | 92.43M | 85.98M | 6.04M |
| TangibleBookValue | 240.97M | 150.87M | 99.43M | 160.78M |
| InvestedCapital | 273.04M | 180.91M | 128.72M | 160.78M |
| WorkingCapital | 256.77M | 164.42M | 106.82M | 144.31M |
| NetTangibleAssets | 240.97M | 150.87M | 99.43M | 160.78M |
| CapitalLeaseObligations | 65.31M | 62.39M | 56.69M | 6.04M |
| CommonStockEquity | 240.97M | 150.87M | 99.43M | 160.78M |
| TotalCapitalization | 273.04M | 177.57M | 128.72M | 160.78M |
| TotalEquityGrossMinorityInterest | 240.97M | 150.87M | 99.43M | 160.78M |
| StockholdersEquity | 240.97M | 150.87M | 99.43M | 160.78M |
| GainsLossesNotAffectingRetainedEarnings | 51.00K | 0.00 | ||
| OtherEquityAdjustments | 51.00K | |||
| RetainedEarnings | -375.10M | -247.60M | -158.38M | -92.16M |
| AdditionalPaidInCapital | 616.01M | 398.46M | 257.81M | 252.93M |
| CapitalStock | 6.00K | 5.00K | 3.00K | 3.00K |
| CommonStock | 6.00K | 5.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 130.15M | 121.28M | 99.66M | 27.33M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 94.19M | 91.46M | 82.35M | 5.99M |
| OtherNonCurrentLiabilities | 135.00K | 49.00K | 97.00K | |
| NonCurrentDeferredLiabilities | 1.25M | 5.62M | 0.00 | 1.50M |
| NonCurrentDeferredRevenue | 1.25M | 5.62M | 0.00 | 1.50M |
| LongTermDebtAndCapitalLeaseObligation | 92.81M | 85.84M | 82.30M | 4.39M |
| LongTermCapitalLeaseObligation | 60.74M | 59.14M | 53.01M | 4.39M |
| LongTermDebt | 32.07M | 26.70M | 29.29M | |
| CurrentLiabilities | 35.96M | 29.82M | 17.30M | 21.34M |
| OtherCurrentLiabilities | 76.00K | 425.00K | 431.00K | 1.01M |
| CurrentDeferredLiabilities | 11.70M | 10.14M | 3.87M | 11.41M |
| CurrentDeferredRevenue | 11.70M | 10.14M | 3.87M | 11.41M |
| CurrentDebtAndCapitalLeaseObligation | 4.57M | 6.59M | 3.68M | 1.65M |
| CurrentCapitalLeaseObligation | 4.57M | 3.25M | 3.68M | 1.65M |
| CurrentDebt | 3.35M | |||
| OtherCurrentBorrowings | 3.35M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.84M | 5.48M | 4.36M | 2.60M |
| PayablesAndAccruedExpenses | 12.77M | 7.19M | 4.96M | 4.67M |
| CurrentAccruedExpenses | 8.49M | 4.81M | 2.05M | 2.90M |
| Payables | 4.28M | 2.37M | 2.91M | 1.76M |
| AccountsPayable | 4.28M | 2.37M | 2.91M | 1.76M |
| TotalAssets | 371.12M | 272.15M | 199.09M | 188.11M |
| TotalNonCurrentAssets | 78.40M | 77.91M | 74.96M | 22.45M |
| OtherNonCurrentAssets | 6.80M | 6.68M | 5.76M | 5.20M |
| NonCurrentPrepaidAssets | 166.00K | |||
| NetPPE | 71.60M | 71.23M | 69.20M | 17.26M |
| AccumulatedDepreciation | -18.70M | -14.60M | -10.22M | -5.08M |
| GrossPPE | 90.30M | 85.83M | 79.42M | 22.34M |
| Leases | 3.26M | 3.16M | 3.45M | 3.43M |
| ConstructionInProgress | 100.00K | 548.00K | 5.00K | 1.26M |
| OtherProperties | 83.73M | 79.14M | 13.75M | 16.85M |
| MachineryFurnitureEquipment | 3.22M | 2.98M | 62.22M | 793.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 292.72M | 194.24M | 124.13M | 165.65M |
| OtherCurrentAssets | 2.61M | 2.19M | 4.10M | 4.25M |
| PrepaidAssets | 4.25M | |||
| CashCashEquivalentsAndShortTermInvestments | 290.11M | 192.04M | 120.03M | 161.41M |
| OtherShortTermInvestments | 111.42M | 58.69M | 0.00 | |
| CashAndCashEquivalents | 178.69M | 133.36M | 120.03M | 161.41M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -114.65M | -64.50M | -70.73M | -58.62M |
| RepaymentOfDebt | -17.14M | 0.00 | ||
| IssuanceOfDebt | 32.46M | 0.00 | 29.35M | 0.00 |
| IssuanceOfCapitalStock | 33.13M | 42.41M | 193.00K | 189.38M |
| CapitalExpenditure | -3.83M | -3.15M | -4.22M | -9.94M |
| InterestPaidSupplementalData | 2.88M | 3.00M | 660.00K | 0.00 |
| EndCashPosition | 183.72M | 138.39M | 125.06M | 166.44M |
| BeginningCashPosition | 138.39M | 125.06M | 166.44M | 35.39M |
| ChangesInCash | 45.33M | 13.33M | -41.37M | 131.05M |
| FinancingCashFlow | 208.76M | 135.44M | 29.36M | 189.67M |
| CashFlowFromContinuingFinancingActivities | 208.76M | 135.44M | 29.36M | 189.67M |
| NetOtherFinancingCharges | -324.00K | |||
| ProceedsFromStockOptionExercised | 160.32M | 93.03M | 133.00K | 291.00K |
| NetPreferredStockIssuance | 0.00 | 99.73M | ||
| PreferredStockIssuance | 0.00 | 99.73M | ||
| NetCommonStockIssuance | 33.13M | 42.41M | 193.00K | 89.65M |
| CommonStockIssuance | 33.13M | 42.41M | 193.00K | 89.65M |
| NetIssuancePaymentsOfDebt | 15.31M | 0.00 | 29.35M | 0.00 |
| NetLongTermDebtIssuance | 15.31M | 0.00 | 29.35M | 0.00 |
| LongTermDebtPayments | -17.14M | 0.00 | ||
| LongTermDebtIssuance | 32.46M | 0.00 | 29.35M | 0.00 |
| InvestingCashFlow | -52.61M | -60.76M | -4.22M | -9.94M |
| CashFlowFromContinuingInvestingActivities | -52.61M | -60.76M | -4.22M | -9.94M |
| NetInvestmentPurchaseAndSale | -48.79M | -57.61M | 0.00 | |
| SaleOfInvestment | 192.66M | 20.00M | 0.00 | |
| PurchaseOfInvestment | -241.44M | -77.61M | 0.00 | |
| NetPPEPurchaseAndSale | -3.83M | -3.15M | -4.22M | -9.94M |
| PurchaseOfPPE | -3.83M | -3.15M | -4.22M | -9.94M |
| OperatingCashFlow | -110.82M | -61.36M | -66.50M | -48.68M |
| CashFlowFromContinuingOperatingActivities | -110.82M | -61.36M | -66.50M | -48.68M |
| ChangeInWorkingCapital | 5.05M | 17.61M | -10.23M | -5.90M |
| ChangeInOtherWorkingCapital | -934.00K | 12.82M | -11.08M | -6.54M |
| ChangeInPayablesAndAccruedExpense | 6.53M | 3.80M | 1.26M | 3.24M |
| ChangeInAccruedExpense | 4.53M | 3.85M | 732.00K | 3.23M |
| ChangeInPayable | 1.99M | -52.00K | 528.00K | 10.00K |
| ChangeInAccountPayable | 1.99M | -52.00K | 528.00K | 10.00K |
| ChangeInPrepaidAssets | -538.00K | 985.00K | -410.00K | -2.60M |
| OtherNonCashItems | 773.00K | 757.00K | 260.00K | |
| StockBasedCompensation | 9.55M | 5.21M | 4.55M | 2.52M |
| AmortizationOfSecurities | -3.90M | -1.07M | 0.00 | |
| DepreciationAmortizationDepletion | 4.11M | 5.36M | 5.14M | 3.33M |
| DepreciationAndAmortization | 4.11M | 5.36M | 5.14M | 3.33M |
| Depreciation | 4.11M | 5.36M | 5.14M | |
| OperatingGainsLosses | 1.09M | |||
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -127.50M | -89.22M | -66.22M | -48.62M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TCRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|